ThreeVix Signs Business Agreement with Jeonbuk National University Hospital Functional Food Clinical Trial Support Center

Establishment of a Microbiome-Based Food Clinical Support System

Park Jun-hyung, CEO of Three Vics (from the left), and Chae Su-wan, Director of the Functional Food Clinical Trial Support Center at Jeonbuk National University Hospital, are posing for a commemorative photo.

[Asia Economy Reporter Kim Young-won] On the 10th, ThreeVix announced that on the 9th, it signed a Memorandum of Understanding (MOU) with Jeonbuk National University Hospital's Functional Food Clinical Trial Support Center to establish a microbiome-based food clinical support system.

At the signing ceremony held at Jeonbuk National University Hospital's Clinical Research Support Center, both institutions agreed to jointly promote research and system development for global food certification based on ThreeVix's accumulated bio big data and microbiome analysis technology and the Functional Food Clinical Trial Support Center's expertise in food clinical trials.

ThreeVix is a precision medical platform company based on bio big data, providing NGS-based multi-omics analysis and bio data platform construction services.

Through this MOU, the Center and ThreeVix will comprehensively collaborate in various fields including ▲ joint project cooperation integrating microbiome, disease, and dietary clinical information ▲ building big data and AI technology cooperation for new drugs, health functional foods, diet, and microbiome ▲ joint development of personalized microbiome, disease, and dietary treatment databases ▲ development of medifood and aging food based on microbiome information analysis.

The microbiome is being promoted as a new growth engine across all sectors including food, pharmaceuticals, and beauty. According to market research firm Frost & Sullivan, the global microbiome market is expected to grow to $108.7 billion (approximately 148 trillion KRW) in 2023, with an average annual growth rate of 7.6%.

Center Director Chae Su-wan stated, "Through this collaboration, we will establish clearer standards for food clinical trials and create synergy in various microbiome-based research and commercialization by linking bio big data and AI technology."

ThreeVix CEO Park Jun-hyung said, "Based on joint research and cooperation with the Center, we will pioneer not only the domestic but also the global microbiome analysis and diagnostic market and the therapeutic market through food."

This content was produced with the assistance of AI translation services.